{
    "id": 26826,
    "fullName": "SMAD4 Q83*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMAD4 Q83* results in a premature truncation of the Smad4 protein at amino acid 83 of 552 (UniProt.org). Q83* has not been characterized however, due to the effects of other truncation mutations downstream of Q83 (PMID: 11553622, PMID: 22316667), Q83* is predicted to lead to a loss of Smad4 protein function.",
            "references": [
                {
                    "id": 3669,
                    "pubMedId": 22316667,
                    "title": "Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22316667"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 3668,
                    "pubMedId": 11553622,
                    "title": "Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11553622"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4089,
        "geneSymbol": "SMAD4",
        "terms": [
            "SMAD4",
            "DPC4",
            "JIP",
            "MADH4",
            "MYHRS"
        ]
    },
    "variant": "Q83*",
    "createDate": "07/28/2017",
    "updateDate": "02/27/2019",
    "referenceTranscriptCoordinates": {
        "id": 141779,
        "transcript": "NM_005359",
        "gDna": "chr18:g.51047293C>T",
        "cDna": "c.247C>T",
        "protein": "p.Q83*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11543,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28131,
                "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11544,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",
            "molecularProfile": {
                "id": 28131,
                "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9613,
                    "pubMedId": 28476735,
                    "title": "Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476735"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28130,
            "profileName": "SMAD4 Q83*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28131,
            "profileName": "EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 141779,
            "transcript": "NM_005359",
            "gDna": "chr18:g.51047293C>T",
            "cDna": "c.247C>T",
            "protein": "p.Q83*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}